Ticker > Company >

Kwality Pharma share price

Kwality Pharmaceuticals Ltd.

BSE: 539997 SECTOR: Pharmaceuticals & Drugs  43k   352   14

867.00
+12.85 (1.50%)
BSE: 20 Dec 04:01 PM

Price Summary

Today's High

₹ 874.9

Today's Low

₹ 849.05

52 Week High

₹ 961.15

52 Week Low

₹ 371.55

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

899.62 Cr.

Enterprise Value

992.7 Cr.

No. of Shares

1.04 Cr.

P/E

30.97

P/B

3.72

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  233.22

CASH

5.04 Cr.

DEBT

98.12 Cr.

Promoter Holding

54.83 %

EPS (TTM)

₹  28

Sales Growth

22.38%

ROE

11.25 %

ROCE

13.62%

Profit Growth

23.19 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year22.38%
3 Year5.51%
5 Year13.21%

Profit Growth

1 Year23.19%
3 Year15.88%
5 Year26.02%

ROE%

1 Year11.25%
3 Year40.01%
5 Year33.72%

ROCE %

1 Year13.62%
3 Year41.03%
5 Year33.62%

Debt/Equity

0.4358

Price to Cash Flow

20.75

Interest Cover Ratio

4.0295

CFO/PAT (5 Yr. Avg.)

0.943547173195236

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 54.83 0.00
Jun 2024 54.83 0.00
Mar 2024 54.83 0.00
Dec 2023 54.77 0.00
Sep 2023 54.77 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 15.8756256059221% for the Past 3 years.
  • Company has been maintaining healthy ROE of 40.0106036927751% over the past 3 years.
  • Company has been maintaining healthy ROCE of 41.0278191551151% over the past 3 years.
  • The Company has been maintaining an effective average operating margins of 20.9927885757013% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 48.4025 days.
  • The company has a high promoter holding of 54.83%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.60320519964994.

 Limitations

  • The company has shown a poor revenue growth of 5.51191096384387% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 69.65 78.1 91.98 80.08 90.03
Total Expenditure 54.38 61.39 71.12 62.72 70.35
Operating Profit 15.27 16.7 20.86 17.36 19.68
Other Income 0.23 0.62 0.58 0.28 0.22
Interest 2.41 2.73 3.06 2.48 2.71
Depreciation 4.88 4.81 5.04 4.02 4.61
Exceptional Items 0 0 -7.1 0 0
Profit Before Tax 8.21 9.78 6.24 11.14 12.58
Tax 1.95 2.07 1.75 2.77 4.1
Profit After Tax 6.26 7.7 4.5 8.37 8.48
Adjusted EPS (Rs) 6.03 7.42 4.33 8.06 8.18

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 138.68 261.5 456.13 250.99 307.17
Total Expenditure 124.57 232.24 284.41 190.12 240.54
Operating Profit 14.12 29.26 171.72 60.88 66.63
Other Income 3.92 1.59 3.51 2.94 1.83
Interest 2.5 2.62 2.92 6.61 10.39
Depreciation 4.39 6.44 10.64 14.92 19.51
Exceptional Items 0 0 0 -16.53 -7.1
Profit Before Tax 11.14 21.8 161.67 25.76 31.47
Tax 2.71 6.38 41.63 6.29 7.48
Net Profit 8.43 15.42 120.05 19.47 23.98
Adjusted EPS (Rs.) 8.13 14.86 115.69 18.76 23.11

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 10.38 10.38 10.38 10.38 10.38
Total Reserves 36.72 52.13 172.18 191.65 215.57
Borrowings 10.18 18.26 20.29 27.3 19.56
Other N/C liabilities 9.6 9.82 1.03 1.31 0.19
Current liabilities 67.61 78.15 138.8 125.94 151.85
Total Liabilities 134.48 168.75 342.68 356.58 397.55
Assets
Net Block 41.63 55.52 90.77 119.57 138.18
Capital WIP 0 2.89 12.15 14.29 0
Intangible WIP 0 0 0 0 0
Investments 4.2 4.28 3.55 3.55 3.55
Loans & Advances 0.12 0.17 8.11 10.71 12.44
Other N/C Assets 0 0 0.78 0.93 0
Current Assets 88.53 105.88 227.32 207.52 243.38
Total Assets 134.48 168.75 342.68 356.58 397.55
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 11.14 21.8 161.67 25.76 31.47
Adjustment 6.27 8.98 13.51 20.91 36.61
Changes in Assets & Liabilities -9.06 1.96 -74.59 1.67 -23.43
Tax Paid -2.71 -6.38 -41.35 -6.16 -1.3
Operating Cash Flow 5.63 26.36 59.24 42.19 43.35
Investing Cash Flow -17.13 -23.2 -62.98 -48.44 -26.4
Financing Cash Flow 12.36 0.83 5.66 0.99 -17.4
Net Cash Flow 0.87 3.99 1.93 -5.26 -0.45

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 54.77 54.77 54.83 54.83 54.83
aditya arora 11.89 11.89 11.95 11.95 11.95
ajay arora 13.59 13.59 13.59 13.59 13.59
anju arora 1.31 1.31 1.31 1.31 1.31
geeta arora 1.07 1.07 1.07 1.07 1.07
jugal kishore huf 0.89 0.89 0.89 0.89 0.89
ramesh arora 26.01 26.01 26.01 26.01 26.01
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 45.23 45.23 45.17 45.17 45.17
deepak bansal 10.63 10.63 10.63 10.63 10.63
dheeraj kumar lohia - 1.92 1.92 1.92 1.92
investor education and pr... - - 0.97 0.97 0.97
jani bhasha shaik 1.45 1.45 1.45 1.45 1.45
kadayam ramnathan bharat - 1.16 1.66 1.88 1.88
manohar devabhaktuni 4.98 4.98 4.98 4.98 4.98
onkar singh 1.02 1.02 1.02 1.02 1.06

Ratings & Research Reports

Company Presentations

Company News

Kwality Pharmaceuticals informs about disclosure 26 Nov, 5:02 PM Kwality Pharmaceuticals informs about updates 26 Nov, 4:46 PM Kwality Pharmaceutical gets approval for manufacturing and sale of PEGylated-Asparaginase 26 Nov, 3:59 PM Kwality Pharmaceuticals gets nod for Leuprorelin Acetate 11.25 mg vial powder & solvent for injectable suspension 6 Nov, 5:44 PM Kwality Pharma - Quaterly Results 30 Oct, 6:31 PM Kwality Pharma - Quaterly Results 30 Oct, 6:31 PM Kwality Pharma - Quaterly Results 10 Aug, 6:42 PM Kwality Pharma - Quaterly Results 10 Aug, 6:42 PM Kwality Pharma - Quaterly Results 10 Aug, 6:42 PM Kwality Pharma - Quaterly Results 23 May, 8:20 PM Kwality Pharma - Quaterly Results 23 May, 8:20 PM Kwality Pharma - Quaterly Results 6 Feb, 7:40 PM Kwality Pharma - Quaterly Results 6 Feb, 7:40 PM Kwality Pharmaceuticals informs about confirmation certificate 15 Jan, 12:19 PM Kwality Pharma - Quaterly Results 4 Nov, 8:48 PM Kwality Pharma - Quaterly Results 10 Aug, 7:21 PM Kwality Pharma - Quaterly Results 10 Aug, 7:21 PM Kwality Pharmaceuticals informs about disclosure 1 Jul, 2:20 PM Kwality Pharmaceuticals informs about disclosure 9 Jun, 12:15 PM Kwality Pharma - Quaterly Results 27 May, 8:12 PM Kwality Pharmaceuticals gets EU GMP approval for Himachal Pradesh facility 24 Apr, 5:58 PM Kwality Pharmaceuticals informs about change in directorate 17 Mar, 2:38 PM Kwality Pharma - Quaterly Results 14 Feb, 8:30 PM Kwality Pharmaceuticals informs about disclosure 21 Jan, 3:45 PM Kwality Pharmaceuticals informs about disclosure 21 Jan, 2:56 PM Kwality Pharmaceuticals informs about confirmation certificate 10 Jan, 11:51 AM Bulgarian Drug Agency accepts Kwality Pharmaceuticals’ application for EU Audit visit of HP plant 28 Dec, 9:57 AM Kwality Pharmaceuticals gets approval from Brazil's ANVISA 21 Dec, 4:00 PM Kwality Pharmaceuticals informs about disclosure of related party transactions 29 Nov, 9:42 AM Kwality Pharma - Quaterly Results 14 Nov, 12:00 PM Kwality Pharmaceuticals informs about press release 17 Aug, 12:31 PM Kwality Pharmaceuticals informs about disclosure 27 Jun, 11:16 AM Kwality Pharmaceuticals informs about closure of trading window 1 Apr, 9:49 AM Kwality Pharmaceuticals informs about disclosure 28 Feb, 9:29 AM Kwality Pharmaceuticals informs about disclosure 5 Feb, 2:48 PM Kwality Pharmaceuticals informs about confirmation certificate 18 Jan, 10:11 AM Kwality Pharmaceuticals informs about annual report 8 Sep, 9:54 AM Kwality Pharmaceuticals informs about disclosure 26 Jun, 11:13 AM

Kwality Pharma Stock Price Analysis and Quick Research Report. Is Kwality Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Kwality Pharma and its performance over the period of time. Kwality Pharma stock price today is Rs 867.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Kwality Pharma cash from the operating activity was Rs 43.3473 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Kwality Pharma has a Debt to Equity ratio of 0.4358 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Kwality Pharma , the EPS growth was 23.1915 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Kwality Pharma has OPM of 21.6925186491729 % which is a good sign for profitability.
     
  • ROE: Kwality Pharma have a average ROE of 11.2503 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Kwality Pharma is Rs 867. One can use valuation calculators of ticker to know if Kwality Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Kwality Pharma
X